Agios Pharmaceuticals is a biopharmaceutical company focused on areas of hematologic malignancies, solid tumors and rare genetic diseases. The company's product, TIBSOVO? (ivosidenib) is for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase (IDH) 1 mutation. The company's other product is IDHIFA? (enasidenib) for patients with R/R AML and an IDH2 mutation. The company's pre-commercial clinical cancer product candidates include: vorasidenib, a brain-penetrant pan-IDH mutant inhibitor; and AG-270, an orally available selective inhibitor of methionine adenosyltransferase 2a.

Alector is a clinical stage biopharmaceutical company. The company is engaged in developing immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The company's preclinical and clinical programs include: AL001, which is the company's progranulin (PGRN) product candidate in clinical development, is designed to treat frontotemporal dementia, a severe, rapidly progressing neurodegenerative disorder: AL101, which is the company's second PGRN product candidate that is being developed for the indications, such as Alzheimer's disease and Parkinson's disease; and AL002 and AL003, which are candidate for Alzheimer's disease.

Altimmune is a clinical stage immunotherapeutics company focused on the discovery and development of products to stimulate immune responses for the prevention and treatment of diseases. The company's product candidates include: HepTcell, an immunotherapeutic for patients infected with the hepatitis B virus; ALT-702, a tumor immunostimulant designed to elicit or improve immune responses to cancers; NasoVAX, an intranasally administered recombinant influenza vaccine which stimulates an immune response; NasoShield, an anthrax vaccine designed to provide protection after a single intranasal administration; and SparVax-L, a recombinant protein-based anthrax vaccine designed to require fewer doses.

Amicus Therapeutics is a biotechnology company focused on the discovering, developing, and delivering medicines for diseases. The company's Commercial Product and Product Candidates include Galafold? (Migalastat HCl), which is for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; Enzyme Replacement Therapy for Pompe disease; and Cyclin-dependent kinase-like 5 (CDKL5) Deficiency Disorder, which is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development.

Anavex Life Sciences is a clinical stage biopharmaceutical company engaged in the development of therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company's primary compound, ANAVEX?2-73, is being developed to treat Alzheimer's disease, Parkinson's disease and other central nervous system diseases, including rare diseases, such as Rett syndrome. The company's proprietary SIGMACEPTOR? Discovery Platform produced small molecule drug candidates with certain modes of action, based on its understanding of sigma receptors. Compounds that have been subjects of the company's research include the following: ANAVEX?3-71, ANAVEX?1-41, ANAVEX?1066, and ANAVEX?1037.

AVEO Pharmaceuticals is a biopharmaceutical company. The company's product candidates include: tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody for the treatment of a potential treatment for squamous cell carcinoma of the head and neck, acute myeloid leukemia; AV-203, an anti-ErbB3 specific monoclonal antibody with high ErbB3 affinity; AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 an inhibitory antibody specific to Notch 3 a pathway in cell-to-cell communication.

Chewy is a pure play e-commerce business geared toward pet products for dogs, cats, fish, birds, small pets, horses, and reptiles. The company serves its customers through its retail website, www.chewy.com, and its mobile applications and focuses on delivering exceptional customer service, a large selection of high-quality pet food, treats and supplies, price, convenience (including Chewy's Autoship subscription program), fast shipping, and hassle-free returns.

Cryoport provides temperature controlled logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and cold chain logistics knowhow. The company's services are utilized for temperature-controlled shipping and storage and information in the life sciences industry, which includes personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision controlled temperatures.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company's clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure, AMG 594, a cardiac troponin activator, reldesemtiv, a skeletal muscle troponin activator for the treatments of spinal muscular atrophy and amyotrophic lateral sclerosis, and CK-3773274, a cardiac myosin inhibitor which is designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy.

Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. The company's target indications include diseases, such as Alzheimer's disease and Parkinson's disease, as well as orphan indications, such as mucopolysaccharidosis type II, and amyotrophic lateral sclerosis. The company's Transport Vehicle technology enables several classes of biotherapeutics to cross the blood-brain barrier (BBB), including enzymes, antibodies, proteins and oligonucleotides. This technology is designed to engage BBB transport receptors, which are expressed in brain capillaries and facilitate transport of proteins into the brain.

Funko is holding company. Through its subsidiaries, the company is a pop culture consumer products company. The company sells various licensed pop culture consumer products featuring characters from a range of media and entertainment content, including movies, TV shows, video games, music and sports. The company's product categories include: Figures, which includes figures that celebrate pop culture icons in the form of stylized vinyl, blind-packed miniatures and action figures; and Other, which includes plush products that are soft-sculpt figures; apparel (including t-shirts and hats); homewares (including drinkware, party lights and other home accessories); and stylized bags, purses and wallets and board games.

Health Catalyst is a provider of data and analytics technology and services to healthcare organizations. The company designs, develops, and delivers healthcare software solutons for hospitals to manage operational, financial, clinical, and research data. The company serves customers in the State of Utah.

Intellia Therapeutics is a genome editing company focused on developing therapeutics utilizing a biological tool known as Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9). This is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. The company utilizes its CRISPR/Cas9 platform across two areas: in vivo applications, in which CRISPR/Cas9 is therapy, delivered to target cells within the body; and ex vivo applications, in which CRISPR/Cas9 creates therapy of engineered human cells.

Radius Health is a biopharmaceutical company focused on developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's commercial product, TYMLOSTM (abaloparatide) injection is designed for the treatment of postmenopausal women with osteoporosis at high risk for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The company is developing an abaloparatide transdermal patch for potential use in the treatment of postmenopausal women with osteoporosis. The company is also developing its Elacestrant, a selective estrogen receptor degrader, for potential use in the treatment of hormone receptor-positive breast cancer.

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company is engaged in developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases by utilizing its proprietary drug discovery and development engine. The company's oncology drug candidate, FLX475, inhibits the migration of immunosuppressive regulatory T cells into tumors. The company's inflammation drug candidate, RPT193, inhibits the migration of type 2 T helper cells, into allergically-inflamed tissues.

Rite Aid is a pharmacy retail healthcare company. The company's Retail Pharmacy segment sells brand and generic prescription drugs, as well as an assortment of front-end products including health and beauty aids, personal care products, seasonal merchandise, and a private brand product line. The company's Pharmacy Services segment provides pharmacy benefit management (PBM) options through its EnvisionRxOptions and MedTrak PBMs, respectively. EnvisionRxOptions also provides mail-order and specialty pharmacy services through EnvisionPharmacies; a claims adjudication software platform in Laker Software; and a national Medicare Part D prescription drug plan through its EnvisionRx Plus product offering.

Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. The company has the following inical-stage ex vivo lentiviral vector programs enrolling patients in the U.S. and European Union for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

Sprout Social is a social media technology platform. The company's cloud software brings together social messaging, data and workflows in a unified system of record, intelligence and action. Operating across major social media networks, including Twitter, Facebook, Instagram, Pinterest, LinkedIn, Google and YouTube, the company provides organizations with a centralized platform to effectively manage their social media efforts across stakeholders and business functions. The company's platform can be deployed by new customers without direct engagement from its sales or services teams. The company operates a single code-base without the need for customizations or professional services.

TransMedics is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company developed the Organ Care System ("OCS") to replace a decades-old standard of care. The OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. The company's OCS technology replicates many aspects of the organ's natural living and functioning environment outside of the human body.

Veracyte is a genomic diagnostics company. The company's products include the following: Afirma Genomic Sequencing Classifier and Xpression Atlas, which includes the Afirma GSC and Xpression Atlas; Percepta Bronchial Genomic Classifier, which improves lung cancer diagnosis by improving the performance of diagnostic bronchoscopies; Envisia Genomic Classifier, which improves diagnosis of idiopathic pulmonary fibrosis; and Prosigna Breast Cancer Prognostic Gene Signature Assay, which uses genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease.

Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat diseases with unmet medical needs. The company is developing a suite of clinical-stage drug candidates from its proprietary XmAb? technology platforms that are designed to treat cancer and autoimmune diseases. The company's protein engineering knowledge and the XmAb technologies are focused on the parts of the antibody that interacts with various segments of the immune system and controls antibody structure. This segment, referred to as the Fc domain, is constant and interchangeable among antibodies.